BioLife Solutions, Inc. BLFS 深 滬
已收盤 02-06 16:00:00 美东时间
22.43
+0.410
+1.86%
華盛通- 最 高22.66
- 今 開22.00
- 成交量 45.35万股
- 最 低 21.35
- 昨 收 22.02
- 總市值 10.80亿
- 52周最高 29.62
- 市盈率 靜 --
- 換手率 0.94%
- 52周最低 19.10
- 委 比 -61.87%
- 總股本 4814.80万
- 歷史最高 60.669
- 量 比 0.76
- 振 幅 5.95%
- 歷史最低 0.02
- 每 手 1
- 風險率 2.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅908.06%！Piper Sandler首予Palisade Bio(PALI)"超配"评级，目标价25美元
今日重点评级关注：Needham：维持Autolus Therapeutics"买入"评级，目标价从10美元升至11美元；BTIG：维持Praxis Precision Medicine"买入"评级，目标价从507美元升至843美元
2025-12-30 10:04
HC Wainwright & Co. Reiterates Buy on BioLife Solutions, Maintains $32 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates BioLife Solutions (NASDAQ:BLFS) with a Buy and maintains $32 price target.
2025-12-29 19:43
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
BioLife Solutions Unveils the Aby J. Mathew Center for Biopreservation Excellence
New conference and laboratory facility to showcase the company's product portfolio and serve as a research and training hub to advance biopreservation and cell processing innovation BOTHELL,...
2025-11-20 21:04
电话会总结 ｜ BioLife(BLFS)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据BioLife Solutions 2025年第三季度业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收2,810万美元，同比增长31% - 细胞处理业务营收2,540万美元，同比增长33%（剔除130万美元提前发货订单后，同比增长26%） - 生物保存介质(BPM)占细胞处理营收80%以上 **盈利能力：** - GAAP毛利率62%，较去年同期63%略有下降 - 调整后毛利率64%，较去年同期67%下降，主要受60万美元一次性库存准备金和产品组合变化影响 - GAAP净利润62.1万美元（每股0.01美
2025-11-10 12:08
BioLife Solutions shares are trading lower after the company reported Q3 financial results and cut it sFY25 sales guidance below estimates.
BioLife Solutions shares are trading lower after the company reported Q3 financ...
2025-11-08 01:33
BioLife Solutions Lowers FY2025 Sales Guidance from $100.000M-$103.000M to $95.000M-$96.000M vs $101.322M Est
BioLife Solutions (NASDAQ:BLFS) lowers FY2025 sales outlook from $100.000 million-$103.000 million to $95.000 million-$96.000 million vs $101.322 million estimate.
2025-11-07 05:08
BioLife Solutions Sells Cold Chain Logistics Subsidiary, SAVSU Cleo Technologies, For $25.5M In Cash To Peli BioThermal
BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools for the cell and gene therapy ("CGT") market, announces the sale of SAVSU Cleo
2025-10-07 20:10
BioLife Solutions Holds Annual Stockholders Meeting
BioLife Solutions ( ($BLFS) ) has issued an update. On August 20, 2025, BioLife...
2025-08-22 04:48
HC Wainwright & Co. Maintains Buy on BioLife Solutions, Raises Price Target to $32
HC Wainwright & Co. analyst Yi Chen maintains BioLife Solutions (NASDAQ:BLFS) with a Buy and raises the price target from $30 to $32.
2025-08-08 18:38
